CHEK2 mutation
|
Prostate Cancer
|
CHEK2 mutation
|
Prostate Cancer
|
olaparib Sensitive: A2 - Guideline
|
olaparib Sensitive: A2 - Guideline
|
CHEK2 mutation
|
Ovarian Cancer
|
CHEK2 mutation
|
Ovarian Cancer
|
olaparib Sensitive: B - Late Trials
|
olaparib Sensitive: B - Late Trials
|
CHEK2 mutation
|
HER2 Negative Breast Cancer
|
CHEK2 mutation
|
HER2 Negative Breast Cancer
|
durvalumab Sensitive: C2 – Inclusion Criteria
|
durvalumab Sensitive: C2 – Inclusion Criteria
|
CHEK2 mutation
|
HER2 Negative Breast Cancer
|
CHEK2 mutation
|
HER2 Negative Breast Cancer
|
talazoparib Sensitive: C3 – Early Trials
|
talazoparib Sensitive: C3 – Early Trials
|
CHEK2 mutation
|
Breast Cancer
|
CHEK2 mutation
|
Breast Cancer
|
CDK6 inhibitor Resistant: C3 – Early Trials
|
CDK6 inhibitor Resistant: C3 – Early Trials
|
CHEK2 mutation
|
Breast Cancer
|
CHEK2 mutation
|
Breast Cancer
|
CDK4 inhibitor Resistant: C3 – Early Trials
|
CDK4 inhibitor Resistant: C3 – Early Trials
|
CHEK2 mutation
|
Tongue Carcinoma
|
CHEK2 mutation
|
Tongue Carcinoma
|
ABT-888 + M6620 Sensitive: C4 – Case Studies
|
ABT-888 + M6620 Sensitive: C4 – Case Studies
|